—
C+
C+ The full Closelook — membership. Open the C+ overview

Vaxcyte Inc (PCVX) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Vaxcyte Inc

PCVX in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Vaxcyte is a clinical-stage vaccine developer working on conjugate and protein vaccines aimed at bacterial infections. Its lead programmes target pneumococcal disease, with wider-valency candidates meant to cover more strains than existing shots, alongside earlier-stage work on strep, gum disease and dysentery. It holds no approved products yet and depends on trial results to advance its pipeline. It is based in San Carlos, California.
Where it sits in the stack
Vaxcyte carries no seat in our index; it sits in the Healthcare sector, within the biotechnology sleeve of our wider universe, and has no place in any layer of the AI build-out.
Who it is priced against
The diary's peer group has no listed comparison for this name; the market commonly sets it against Pfizer, whose established pneumococcal vaccine occupies the market Vaxcyte's candidates are aimed at.
Why Closelook tracks it
It carries a Closelook score, with momentum reading as its module of note, though it holds no index seat and has not featured in the diary's quotes or editions.
What the diary watches
The diary watches for trial results on its lead pneumococcal candidates, since a readout would move sentiment well before any change shows up in its score.

Vaxcyte Inc (PCVX) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for PCVX, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against PCVX on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Vaxcyte Inc (PCVX)?

Vaxcyte Inc trades as PCVX on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-23.

Is PCVX in a Closelook index?

Not currently — Vaxcyte Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

Where does PCVX trade against its moving averages?

Uptrend stack intact: Trades +0.9% vs the 50-day and +8% vs the 200-day average, 9.2% below the 52-week high and +87.3% off the 52-week low. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Vaxcyte Inc do?

Vaxcyte is a clinical-stage vaccine developer working on conjugate and protein vaccines aimed at bacterial infections. Its lead programmes target pneumococcal disease, with wider-valency candidates meant to cover more strains than existing shots, alongside earlier-stage work on strep, gum disease and dysentery. It holds no approved products yet and depends on trial results to advance its pipeline. The diary's peer group has no listed comparison for this name; the market commonly sets it against Pfizer, whose established pneumococcal vaccine occupies the market Vaxcyte's candidates are aimed at.

Where does Vaxcyte Inc sit in the AI build-out?

Vaxcyte carries no seat in our index; it sits in the Healthcare sector, within the biotechnology sleeve of our wider universe, and has no place in any layer of the AI build-out. It carries a Closelook score, with momentum reading as its module of note, though it holds no index seat and has not featured in the diary's quotes or editions.

What does this page show?

A live price chart with SMA overlays and drawing tools for PCVX, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.